13F Holdings
中文EN

DARE Dare Bioscience, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1401914 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY2,570.3%
TTM net income YoY39.4%
TTM EPS YoY66.7%
Revenue 3-yr CAGR12.2%
Net income 3-yr CAGR—

Margins

Gross margin26.4%
Operating margin-746.1%
Net margin-749.8%
FCF margin-1,279.2%
EBITDA margin-592.2%

Returns

ROE-407.1%
ROA-40.0%
ROIC (approx.)—
Asset turnover0.05x

Leverage & solvency

Liabilities / assets89.4%
Debt / equity0.00x
Current ratio1.23x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.66x
Accruals ratio26.4%
Payout ratio—
Capex / revenue34.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$1.03M$9,784$2.81M$10.00M$0
Cost of revenue$295,799$0———
Gross profit$734,394$9,784———
R&D expense$5.52M$14.31M$21.54M$30.04M$30.62M
SG&A expense$8.76M$9.16M$12.11M$11.24M$8.35M
Operating income-$13.55M-$23.45M-$30.94M-$31.39M-$39.07M
Pretax income-$13.54M-$4.05M-$30.16M-$30.95M-$38.70M
Income tax$0$0$0$0$0
Net income-$13.40M-$4.05M-$30.16M-$30.95M-$38.70M
EBITDA-$11.92M-$23.41M-$30.90M-$31.36M-$39.04M
EPS (basic)-1.20-0.48-4.15-0.37-0.63
EPS (diluted)-1.20-0.48-4.15-0.37-0.63
Weighted avg. shares (diluted)11.18M8.50M7.28M84.57M61.15M
Balance sheet
Cash & equivalents$24.71M$16.00M$10.81M$34.67M$51.67M
Receivables————$0
Current assets$27.06M$18.45M$17.54M$43.04M$55.30M
PP&E, net$1.56M$1.34M$655,975$64,908$26,041
Total assets$32.47M$22.10M$21.28M$43.83M$55.81M
Current liabilities$23.69M$21.61M$20.48M$31.62M$16.05M
Short-term debt—$4,054———
Total liabilities$29.63M$28.11M$26.33M$32.71M$17.05M
Shareholders' equity$2.84M-$6.01M-$5.05M$11.11M$38.75M
Shares outstanding14.50M8.70M8.33M84.83M83.94M
Cash flow statement
Operating cash flow-$9.89M$5.47M-$38.86M-$18.09M-$28.76M
Capital expenditure$385,278$573,046$629,430$63,069$14,524
Free cash flow-$10.27M$4.90M-$39.49M-$18.15M-$28.78M
Investing cash flow-$385,278-$573,046-$629,430-$63,069-$14,524
Financing cash flow$19.28M$354,522$15.64M$1.34M$75.85M
Depreciation & amortization$1.63M$42,325$38,363$24,202$26,413
Stock-based compensation$1.50M$2.20M$2.53M$2.16M$1.60M

Free plan shows the latest 5 periods; Pro shows all 14 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.